Evidence map›Paper›PMID 26934368›Full record

ArticleRadiation research2016

Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.

Moureq Alotaibi, Khushboo Sharma, Tareq Saleh, Lawrence F Povirk, Eric A Hendrickson, David A Gewirtz

Open access · greenAbstract read
In one paragraph

Article in Radiation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 85 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Talazoparib and radiation enhance the senolytic efficacy of venetoclax in therapy-induced senescent triple-negative breast cancer cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Therapy-induced senescent tumor cells in cancer relapse.Journal of the National Cancer Center · 2023
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Moureq Alotaibia   Department of Pharmacology and Toxicology, School of Medicine and.
Khushboo Sharmaa   Department of Pharmacology and Toxicology, School of Medicine and.
Tareq Saleha   Department of Pharmacology and Toxicology, School of Medicine and.
Lawrence F Povirka   Department of Pharmacology and Toxicology, School of Medicine and.
Eric A Hendricksond   Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455.
David A Gewirtza   Department of Pharmacology and Toxicology, School of Medicine and.
University of Minnesota · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
Repair of DNA double-strand breaks with damaged endsR01CA040615 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI POVIRK, LAWRENCE F · 1985 to 2014
$3.2M
The mechanism of Cas9/CRISPR-initiated genome modification in human somatic cellsR01GM088351 · NIGMS · UNIVERSITY OF MINNESOTA · PI HENDRICKSON, ERIC A · 2010 to 2018
$2.3M
Ligase III regulates survival from crisis induced by gradual telomere shorteningR01CA190492 · NCI · UNIVERSITY OF MINNESOTA · PI HENDRICKSON, ERIC A · 2015 to 2019
$1.7M
Ku regulates non-homologous end joining pathways in human somatic cellsR01CA154461 · NCI · UNIVERSITY OF MINNESOTA · PI HENDRICKSON, ERIC A · 2011 to 2015
$1.6M
XLF in double-strand break repair and chemo/radiosensitizationR01CA166264 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HARTMAN, MATTHEW C · 2013 to 2017
$1.5M
NCI NIH HHS CA154461NCI NIH HHS CA166264NCI NIH HHS CA190492NCI NIH HHS CA40615NCI NIH HHS P30CA016059NCI NIH HHS R01 CA040615NCI NIH HHS R01 CA154461NCI NIH HHS R01 CA166264NCI NIH HHS R01 CA190492NIGMS NIH HHS GM088351NIGMS NIH HHS R01 GM088351
6 · The paper itself

Abstract

Radiotherapy continues to be a primary modality in the treatment of cancer. In addition to promoting apoptosis, radiation-induced DNA damage can promote autophagy and senescence, both of which can theoretically function to prolong tumor survival. In this work, we tested the hypothesis that autophagy and/or senescence could be permissive for DNA repair, thereby facilitating tumor cell recovery from radiation-induced growth arrest and/or cell death. In addition, studies were designed to elucidate the involvement of autophagy and senescence in radiosensitization by PARP inhibitors and the re-emergence of a proliferating tumor cell population. In the context of this work, the relationship between radiation-induced autophagy and senescence was also determined. Studies were performed using DNA repair-proficient HCT116 colon carcinoma cells and a repair-deficient ligase IV(-/-) isogenic cell line. Exposure to radiation promoted a parallel induction of autophagy and senescence that was strongly correlated with the extent of persistent H2AX phosphorylation in both cell lines, however, inhibition of autophagy failed to suppress senescence, indicating that the two responses were dissociable. Exposure to radiation resulted in a transient arrest in the HCT116 cells while arrest was prolonged in the ligase IV(-/-) cells, however, both cell lines ultimately recovered proliferative function, which may reflect maintenance of DNA repair capacity. The PARP inhibitors, olaparib and niraparib, increased the extent of persistent DNA damage induced by radiation exposure as well as the extent of both autophagy and senescence. Neither cell line underwent significant apoptosis by radiation exposure alone or in the presence of the PARP inhibitors. Inhibition of autophagy failed to attenuate radiosensitization, indicating that autophagy was not involved in the action of the PARP inhibitors. As with radiation alone, despite sensitization by PARP inhibition, proliferative recovery was evident within a period of 10-20 days. While inhibition of DNA repair via PARP inhibition may initially sensitize tumor cells to radiation via the promotion of senescence, this strategy does not appear to interfere with proliferative recovery, which could ultimately contribute to disease recurrence.

Indexed as

AnimalsApoptosisAutophagyCarcinomaCell ProliferationCellular SenescenceColonic NeoplasmsDNA Breaks, Double-StrandedDNA DamageDNA Ligase ATPDNA LigasesDNA RepairHCT116 CellsHumansMicePoly (ADP-Ribose) Polymerase-1DNA Ligase ATPDNA LigasesPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesRadiation-Sensitizing Agents

Identifiers

PMID26934368
PMCPMC4821451
OpenAlexW2308934048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.